XTREMOLIFE Advancing Sampling and screening of Extremophile Microorganisms for biodiscovery of Bioactive Compounds from Volcanic, Desert, and Polar Ecosystems
- Coordinator
- Wageningen University, Netherlands
- Runs
- 1 October 2025 to 30 September 2029
- Status
- Running
- EU funding
- €4.5m
- Total cost
- €4.5m
- Partners
- 12 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101181714
What the project is doing
In the project's own words, from its summary on CORDIS.
XTREMOLIFE will accelerate the bioprospection & biodiscovery of novel extremophile microorganisms. XTREMOLIFE uniqueness is advancing next-generation sampling technologies tailored for extreme conditions: [1] Enhanced Ferrybox for boats (self-operating), [2] novel XTREMOsensor for hand-held use, and [3] automated microscopic imagery identification. In addition, we explore (a large) biodiversity from 3 extremophilic ecosystems by bioprospecting across 5 regions (Route 1), and 5 untapped culture collections (Route 2).
We will join those two routes by identifying promising extremophilic microorganisms, produced metabolites, elucidating their bioactivity and structure, optimizing their cultivation, and guaranteeing a baseline pathway towards full exploitation. We will focus on microalgae, cyanobacteria, and their associated microbiome, with a particular interest in bacteria and fungi. The culture collections NORCCA (Norway), ACUF (Italy), BEA (Spain), LEGE-CC (Portugal), TII (Abu Dhabi/UAE) will be prospected.
In parallel, we will assess the microbiome and plan sampling from 5 locations: [1] Antarctic, [2] Volcanic aquatic environments in Canary Island, [3]Azores, [4]Mexico, and [5] Abu Dhabi: focusing on hypersaline and extremely hot springs. We will assess the complexity of extremophilic ecology resorting to physical, chemical and biological data gathered. The chemical prospection will cover bioassays in the human, fish and plant health fields.
Bioactive compounds will be isolated, and their structure fully characterized. Together, the consortium will select up to 7 different microbial compounds of interest-producing strains to be cultivated at lab scale, followed by a scale up to TRL 5 (feeding an Exploitation Roadmap). Finally, XTREMOLIFE will cover the legal framework of sampling, preserving and exploiting genetic material. The pathway towards full industrial exploitation (5-10 years after the project) in the various markets of applications will be characterized.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Wageningen University | Wageningen | Netherlands | Coordinator |
| Fundacion Canaria Parque Cientifico Tecnologico De La Universidad De Las Palmas De Gran Canaria | Las Palmas | Spain | Third party |
| Universidad De Huelva | Huelva | Spain | Participant |
| Universidad De Las Palmas De Gran Canaria | Las Palmas De Gran Canaria | Spain | Participant |
| Erdyn Consultants SAS | Paris | France | Participant |
| Algreen BV | Wageningen | Netherlands | Participant |
| Stichting tot Instandhouding van de Diergaarde van het Koninklijk Zoölogisch Genootschap Natura Artis Magistra | Amsterdam | Netherlands | Participant |
| Nord Universitet | Bodo | Norway | Participant |
| Norsk Institutt for Vannforskning Sti | Oslo | Norway | Participant |
| Associacao Oceano Verde Laboratorio Colaborativo Para O Desenvolvimento De Tecnologias E Produtos Verdes Do Oceano | Faro | Portugal | Participant |
| Centro Interdisciplinar De Investigacao Marinha E Ambiental | Matosinhos | Portugal | Participant |
| Fykia Biotech, Lda | Matosinhos | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI